Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269150 · ClinicalTrials.gov registry record · Phase 2
Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study of Allogeneic Hematopoietic Stem Cell, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT02269150 is a Phase 2 study of Allogeneic Hematopoietic Stem Cell that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 59 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02269150, a Phase 2 study of Allogeneic Hematopoietic Stem Cell, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if fecal microbiota transplantation (FMT) will prevent the future development of CDI. This is also known as fecal bacteriotherapy or stool transplant.
Conditions Studied
Interventions
- BIOLOGICAL fecal microbiota transplantation (FMT)
- OTHER No fecal microbiota transplantation (FMT), routine management
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-10 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269150
The ClinicalTrials.gov registry entry for NCT02269150 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allogeneic Hematopoietic Stem Cell appearing as the primary indexed condition, and to 2 interventions - of which fecal microbiota transplantation (FMT) is the first listed.
NCT02269150 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02269150 about?
NCT02269150 is a clinical study titled "Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation". The purpose of this study is to see if fecal microbiota transplantation (FMT) will prevent the future development of CDI. This is also known as fecal bacteriotherapy or stool transplant.
What is the current status of trial NCT02269150?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2014-10. Estimated completion is 2026-10.
What conditions does trial NCT02269150 study?
This clinical trial studies the following conditions: Allogeneic Hematopoietic Stem Cell.
What interventions are being tested in trial NCT02269150?
The interventions under investigation include: fecal microbiota transplantation (FMT) (BIOLOGICAL), No fecal microbiota transplantation (FMT), routine management (OTHER).
Who is sponsoring clinical trial NCT02269150?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02269150 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.